June 29, 2018
FOR IMMEDIATE RELEASEContact:
Kevin D. Ott
Executive Director
BPSA
ottk@socma.com
www.bpsalliance.org
Keynote will Highlight Insights on Next Wave of Innovations in Cell Therapies, Artificial Organs, Nanotechnology
WASHINGTON, D.C. – Innovation and commercialization of the next generation of opportunities in single-use processing and cell therapies will be a key focus of the Bio-Process Systems Alliance (BPSA) 2nd International Single-Use Summit, September 26-28, in Barcelona, Spain.
The Summit includes a mix of technical and pertinent European regulatory matters that highlight the critical need for innovation in the polymer-based bioprocessing industry, to accelerate and advance life-saving cell-growth and cell-harvested immunotherapies.
“BPSA’s mission is to advance single-use worldwide,” said John Boehm of CPC, Chairman of BPSA’s Board of Directors. “Building on a successful run of Summits in the United States from 2011 to 2018, we are now assembling a knowledge base in Europe by hosting our second European event. Our Barcelona Summit features a unique blend of technical and innovation topics for company leaders across the globe with a business stake in single-use systems as users and providers.
“Our Barcelona event will provide context to the current business climate, inclusive of European Union regulatory insights, market growth potentials, as well as the attributes of single-use systems, which make them safe, reliable, cost-effective and sustainable,” said Boehm.
Featured in speakers are:
Barbara Paldus, General Partner, Sekhmet Limited, who will deliver a forward-looking perspective around biotechnology, bioprocessing, cell, gene and tissue therapy advances, and how 3-D printing, high-speed quantum computing and nanotechnology will feature in the creation and delivery of advanced medicines, replacement organs and immunotherapies.
Uwe Gottschalk, Chief Scientific Officer, Lonza (Switzerland), will describe single-use in the context of personalized medicine paradigms.
Cesar Triguerous, Chief Science, Viralgen (Spain), who will speak to the market potential and supply of viral vectors, now far below demand.
Nino Mihokovic, Quality of Medicines Specialist, EMA (UK), who will address the European Medicines Agency (EMA) perspectives and experiences with polymer-based bio-processing systems.
Rounding out the Summit are panel discussions on a variety of topics impacting the industry. View our full agenda here.
“The Barcelona Summit represents the global impact of single-use on modern medicine – real, potential and imagined. The Summit is not only focused on the proven effectiveness of legacy plastic bioprocessing platforms, but also on the ‘next wave’ of business opportunities, with an eye toward GMP, workforce excellence and sustainability,” said BPSA Executive Director Kevin Ott.
The Summit will be held at the Crowne Plaza in Barcelona. Registration and hotel information can be viewed at www.bpsalliance.org.
About BPSA
The Bio-Process Systems Alliance (BPSA) was formed in 2005 as an international corporate member association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. For more information, visit www.bpsalliance.org.
Categorized in: Affiliates